Jyseleca European Launches Could Lift Gloom At Galapagos

Assuming Sole Responsibility From Gilead

 
• By Kevin Grogan

The Belgian biotech is pleased with the launch of its rheumatoid arthritis drug in Germany and the Netherlands and it has also secured a broad label from NICE.

Competitive edge and business advantage concept as a group of hot air balloons racing to the top but an individualleader with a small balloon attached giving the winning competitor an extra boost.
Jyseleca label from NICE could give Galapagos a competitive edge over other JAK inhibitors • Source: Archive

More from New Products

More from Scrip